{"id":415633,"date":"2021-01-15T07:25:52","date_gmt":"2021-01-15T12:25:52","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=415633"},"modified":"2021-01-15T07:25:52","modified_gmt":"2021-01-15T12:25:52","slug":"cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/","title":{"rendered":"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Jan. 15, 2021<\/span> \/PRNewswire\/ &#8212; <b>Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in <span class=\"xn-location\">Poland<\/span>, <span class=\"xn-location\">Slovakia<\/span> and up to three additional countries in <span class=\"xn-location\">Europe<\/span>. Cyxone expects to announce preliminary results in the third quarter of\u00a02021.<\/b><\/p>\n<p>Cyxone recently announced that the company had received regulatory approval to initiate a double-blind placebo-controlled Phase 2 clinical trial of Rabeximod in <span class=\"xn-location\">Poland<\/span>, where the first site was opened in <span class=\"xn-chron\">December 2020<\/span>. The company has also filed for regulatory approval in <span class=\"xn-location\">Slovakia<\/span>, <span class=\"xn-location\">Hungary<\/span> and <span class=\"xn-location\">Ukraine<\/span>, and is preparing for submissions in additional countries. Rabeximod is being evaluated in patients suffering from moderate Covid-19 in need of oxygen treatment but not ventilator support. It&#8217;s novel mode of action in controlling hyperactivated immune cells in the lung holds hope that progression to acute disease can be prevented. <\/p>\n<p>Given a positive study outcome, Cyxone intends to apply for emergency use authorization once a strategic partner has been identified. The company will continue to progress the development of Rabeximod in Covid-19 as well as in other virally induced respiratory diseases and rheumatoid arthritis.<\/p>\n<p>&#8220;We are very excited to have initiated this important study of Rabeximod in Covid-19 patients at the first site in <span class=\"xn-location\">Poland<\/span>. Therapeutics like\u00a0Rabeximod\u00a0have the potential to save lives in this pandemic and in future pandemics involving viral infections of the lungs. While several vaccines are now becoming available, there will always be a need for therapies for patients who cannot take a vaccine, unknowns such as limited duration of effect or loss of effect caused by potential viral mutations as well as other viral infections such as influenza, SARS and viruses yet to emerge&#8221;, comments Cyxone&#8217;s CEO, <span class=\"xn-person\">Tara Heitner<\/span>. <\/p>\n<p>\n        <b><br \/>\n          <b>Contact <\/b><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Tara Heitner<\/span>, CEO<br \/>Tel: +46-70-781-88-08<br \/>Email: <a target=\"_blank\" href=\"mailto:tara.heitner@cyxone.com\" rel=\"nofollow noopener noreferrer\">tara.heitner@cyxone.com<\/a><br \/>Adelgatan 21<br \/>211 22 Malm\u00f6, <span class=\"xn-location\">Sweden<\/span><\/p>\n<p>\n        <b><br \/>\n          <b>About Cyxone <\/b><br \/>\n        <\/b>\n      <\/p>\n<p>Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug\u00a0being evaluated\u00a0for the management of rheumatoid arthritis and\u00a0moderate\u00a0Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, <a target=\"_blank\" href=\"mailto:ca@mangold.se\" rel=\"nofollow noopener noreferrer\">ca@mangold.se<\/a>. For more information, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3038670-1&amp;h=1865468568&amp;u=http%3A%2F%2Fwww.cyxone.com%2F&amp;a=www.cyxone.com\" rel=\"nofollow noopener noreferrer\">www.cyxone.com<\/a>.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3038670-1&amp;h=1981014008&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3038670-1&amp;h=3819412347&amp;u=https%3A%2F%2Fnews.cision.com%2Fcyxone%2Fr%2Fcyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod%2Cc3268714&amp;a=https%3A%2F%2Fnews.cision.com%2Fcyxone%2Fr%2Fcyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod%2Cc3268714\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/cyxone\/r\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod,c3268714<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3038670-1&amp;h=1647390487&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F16882%2F3268714%2F1359731.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F16882%2F3268714%2F1359731.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/16882\/3268714\/1359731.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Open Press release<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod-301209286.html\">http:\/\/www.prnewswire.com\/news-releases\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod-301209286.html<\/a><\/p>\n<p>SOURCE  Cyxone<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO50215&amp;Transmission_Id=202101150722PR_NEWS_USPR_____IO50215&amp;DateId=20210115\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire STOCKHOLM, Jan. 15, 2021 \/PRNewswire\/ &#8212; Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of\u00a02021. Cyxone recently announced that the company had received regulatory approval to initiate a double-blind placebo-controlled Phase 2 clinical trial of Rabeximod in Poland, where the first site was opened in December 2020. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-415633","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Jan. 15, 2021 \/PRNewswire\/ &#8212; Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of\u00a02021. Cyxone recently announced that the company had received regulatory approval to initiate a double-blind placebo-controlled Phase 2 clinical trial of Rabeximod in Poland, where the first site was opened in December 2020. The &hellip; Continue reading &quot;Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-15T12:25:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod\",\"datePublished\":\"2021-01-15T12:25:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/\"},\"wordCount\":482,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO50215&amp;sd=2021-01-15\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/\",\"name\":\"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO50215&amp;sd=2021-01-15\",\"datePublished\":\"2021-01-15T12:25:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO50215&amp;sd=2021-01-15\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO50215&amp;sd=2021-01-15\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/","og_locale":"en_US","og_type":"article","og_title":"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Jan. 15, 2021 \/PRNewswire\/ &#8212; Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of\u00a02021. Cyxone recently announced that the company had received regulatory approval to initiate a double-blind placebo-controlled Phase 2 clinical trial of Rabeximod in Poland, where the first site was opened in December 2020. The &hellip; Continue reading \"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-15T12:25:52+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod","datePublished":"2021-01-15T12:25:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/"},"wordCount":482,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/","name":"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15","datePublished":"2021-01-15T12:25:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO50215&amp;sd=2021-01-15"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyxone-reports-first-covid-19-patient-screened-in-phase-2-clinical-trial-of-rabeximod\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/415633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=415633"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/415633\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=415633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=415633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=415633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}